The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.


Letter to the Editor

Editor, – In the case report on serotonin syndrome precipitated by an over-the-counter cold remedy (Aust Prescr 2006;29:71), several mechanisms that may have caused this were proposed. I would like to add another contributing mechanism which relates to the patient taking methadone 70 mg daily. Although not a cytochrome P450 2D6 (CYP2D6) substrate, methadone is a potent CYP2D6 inhibitor.1 It is possible that methadone is able to convert a CYP2D6 extensive metaboliser to a poor metaboliser. This process is known as phenocopying. There are very few data on methadone altering the pharmacokinetics of dextromethorphan in plasma. However, another CYP2D6 inhibitor, quinidine, can raise plasma dextromethorphan concentrations about 40-fold.2 Hence, the combination of several drugs individually increasing the brain serotonin concentration and the likelihood of methadone increasing the dextromethorphan concentration may also have contributed in part to the patient developing serotonin syndrome.

Andrew Somogyi
Professor and Deputy Head
Discipline of Pharmacology
The University of Adelaide


Andrew Somogyi

Professor and Deputy Head, Discipline of Pharmacology, The University of Adelaide Adelaide

Chris Cameron

Advanced trainee in general medicine, Hutt Hospital, Lower Hutt, New Zealand